Clinical trials: Depressive Disorder, Major
Depression, Major Depressive Disorder
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
- Trial name
- GEMINI (NCT04019704)
- Testing
- AXS-05
- Where
- 43 sites in United States
- Volunteers
- 327 people
- Sponsor
- Axsome Therapeutics, Inc.
Depressive Disorder, Major
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and…
- Trial name
- VENTURA-LT (NCT05518149)
- Testing
- Aticaprant
- Where
- 234 sites in United States, Argentina and 19 more
- Volunteers
- 871 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8…
- Trial name
- NCT04221230
- Testing
- NMRA-335140
- Where
- 38 sites in United States
- Volunteers
- 204 people
- Sponsor
- Neumora Therapeutics, Inc.
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depression
Brain Imaging of Quetiapine Response in Anxious Depression
The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients.
- Trial name
- NCT00982345
- Testing
- quetiapine (Seroquel XR)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Depressive Disorder, Major, Bipolar Disorder
In-person vs. Remote Wellness Support
The study team will use components of the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to compare Cognitive Adaptation Training (CAT) to Remotely delivered Cognitive Adaptation Training (R-CAT)…
- Conditions
- Depressive Disorder, Major, Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
- Trial name
- R-CAT (NCT04526067)
- Testing
- CAT, R-CAT
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder
A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs).
- Trial name
- NCT01250873
- Testing
- LY2216684, Sertraline
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alcohol Dependence, Major Depression
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
STUDY OBJECTIVES: The primary objective of this study is to compare the safety and efficacy of acamprosate versus placebo in the treatment of alcohol dependence in adults with co-occurring mood or anxiety disorders (specifically…
- Conditions
- Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
- Trial name
- NCT00330174
- Testing
- Acamprosate
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medical University of South Carolina
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder, Depression
rTMS for MDD: 5.5cm Rule vs. F3 Targeting
The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
- Trial name
- NCT03378570
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Nicholas Trapp
Depressive Disorder, Major
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy (monoaminergic antidepressant) where sirukumab (administered as a 50 milligram (mg) subcutaneous (SC) injection…
- Trial name
- NCT02473289
- Testing
- Sirukumab 50 mg
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 193 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD).
- Trial name
- NCT02431806
- Testing
- Levomilnacipran, Fluoxetine
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 552 people
- Sponsor
- Forest Laboratories
Major Depression
Increasing Use of Mental Health Services
The purpose of this study is to test the effectiveness of Open Door (previously known as the Treatment Initiation Program [TIP]), a brief psychosocial intervention to address the psychological barriers to care and improve the use…
- Trial name
- OpenDoor (NCT00605358)
- Testing
- Open Door intervention
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
- Trial name
- NCT02085135
- Testing
- ALKS 5461
- Where
- 9 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram
The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers.
- Trial name
- NCT00851006
- Testing
- Creatine Monohydrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Utah
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Depression, Epinephrine, and Platelet Function
Men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesses.
- Trial name
- NCT00166114
- Testing
- Escitalopram, Desipramine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Emory University
Major Depressive Disorder
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect…
- Trial name
- NCT01263093
- Testing
- Clopidogrel, LY2216684
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Combining Medications to Enhance Depression Outcomes
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
- Trial name
- CO-MED (NCT00590863)
- Testing
- Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
- Where
- 15 sites in United States
- Volunteers
- 665 people
- Sponsor
- National Institute of Mental Health (NIMH)